BACTERIOPHAGE THERAPY MARKET ANALYSIS

Bacteriophage Therapy Market, By Targeted Bacteria (Escherichia coli, Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, Salmonella, and Others), By Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis, and Other, By Route of Administration (Oral, Topical, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Global Bacteriophage Therapy Market: Key Developments

On July 11, 2023, Armata Pharmaceuticals, Inc., a biotechnology company, announced that it has received a US$25 million new financing transaction from Innoviva, Inc., a company engaged in the development, commercialization, and financial management of biopharmaceuticals, to advance the company's pipeline of therapeutic phage candidates, including APPA02 and APSA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.
On June 13, 2023, Adaptive Phage Therapeutics (APT) announced that it had received a US$12 million upfront investment from funds managed by AMR Action Fun, the public-private partnership investing in antibiotics. This investment enables the continued clinical progression of APT’s pipeline of phage therapies to combat antimicrobial infections.
On April 30, 2023, Astellas Pharma Inc., a pharmaceutical company, announced the acquisition of Iveric Bio., a company focusing on the discovery and development of novel treatments in the field of ophthalmology. In the acquisition, Iveric Bio will become an indirectly wholly owned subsidiary of Astellas Pharma Inc.
In December 2022, Fixed-Phage Ltd, a company that provides phage solutions, announced that it had received US$1.6 million in funding from Scottish Enterprise, a U.K. based national economic development agency, to further scale the development and commercialization of bacteriophage technology in the fight against antimicrobial resistance.